NOW APPROVED

Verkazia is the first and only topical immunomodulator approved for the treatment of vernal keratoconjunctivitis (VKC) for pediatric and adult use.1

Santen is working to make Verkazia available for patients in the United States. Be the first to know.

SIGN UP NOW

GET MORE INFORMATION ABOUT VERKAZIA

INDICATIONS AND USAGE

Verkazia™ (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for eye injury and contamination: To avoid the potential for eye injury and contamination, advise patient not to touch the vial tip to the eye or other surfaces.

ADVERSE REACTIONS

The most common adverse reactions reported in greater than 5% of patients were eye pain (12%) and eye pruritus (8%), which were usually transitory and occurred during instillation.

Please see Full Prescribing Information.

NDA-214965. Approved on June 23, 2021.

REFERENCE:1. Verkazia [package insert]. Emeryville, CA: Santen Inc.; 2021.

Santen Logo

About Santen USA

Santen is a global specialized company focused solely on ophthalmology. Santen is the exclusive US distributor of Verkazia.

TapClick here for Verkazia Important Safety Information

We use cookies to improve site and user experience, to provide personalized content, and to analyze our traffic. We also share information about your use of our site with our social media, advertising, and analytics partners. By continuing to browse this site and/or clicking ACCEPT, you’re agreeing to our use of cookies. For more information, please access our Privacy Policy.